The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Myeloablative busulfan with cyclophosphamide (BuCy) versus busulfan with fludarabine (BuFlu) in myeloid neoplasms.
Renju V. Raj
No relevant relationships to disclose
Lindsay Dozeman
No relevant relationships to disclose
Anna M Button
No relevant relationships to disclose
Margarida De Magalhaes-Silverman
No relevant relationships to disclose